Development and validation of fixed-time method for the determination of isoxsuprine hydrochloride in commercial dosages forms

Drug Testing and Analysis

Volumn 2, Issue 9, 2010, Pages 442-446

  Rahman, Nafisur ^a   Afaq, Nasheed ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Ammonium cerium (IV) nitrate; Fixed time method; Hydroxylamine hydrochloride; Isoxsuprine hydrochloride; Pharmaceutical analysis

Indexed keywords

ABSORBANCE; AMINES; CERIUM COMPOUNDS; SPECTROPHOTOMETRY;

ABSORBANCES; AMMONIUM CERIUM (IV) NITRATE; COLORED PRODUCTS; DOSAGE FORMS; FIXED TIME METHOD; HYDROXYLAMINE HYDROCHLORIDE; ISOXSUPRINE HYDROCHLORIDE; KINETIC SPECTROPHOTOMETRIC METHODS; PHARMACEUTICAL ANALYSIS; SULPHURIC ACID MEDIUM;

NITRATES;

AMMONIA; CERIUM NITRATE; ISOXSUPRINE; METHOXYAMINE; SULFURIC ACID;

ARTICLE; DRUG DETERMINATION; DRUG DOSAGE FORM; DRUG STRUCTURE; METHODOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ROOM TEMPERATURE; SPECTROPHOTOMETRY;

EID: 77957329143     PISSN: 19427603     EISSN: 19427611     Source Type: Journal    
DOI: 10.1002/dta.153     Document Type: Article

References (30)

1. J. E. F. Reynolds, Martindale. The Extra Pharmacopoeia, 31st Edn, The Pharmaceutical Press: London, 1996, pp. 1577.
2. Martindale. The Extra Pharmacopoeia, 33rd Edn, Royal Pharmaceutical Society: London, 2002, pp. 1624.
3. British Pharmacopoeia, Vol. II, HMSO: London, 1993, pp. 974.
4. G. Musomarra, G. Scarlata, G. Romano, et al. J. Anal. Toxicol. 1987, 11, 154.
5. I. Jane, A. Mekinnon, R. J. Flanagan, J. Chromatogr. 1985, 323, 191.
6. F. Belal, H. A. Al-Malaq, A. A. Al-Majed, et al. J. Liq. Chromatogr. Rel. Technol. 2000, 23, 3175.
7. D. Cova, R. Colombo, G. Cellini, Pharmacology 1983, 27, 117.
8. F. Aly, S. A. Al-Tamimi, A. A. Al-Warthan, J. AOAC. Int. 2000, 83, 1299.
9. J. C. Apostolakis, C. A. Georgiou, M. A. Koupparis, Analyst 1991, 116, 233.
10. C. A. Georgiou, M. A. Koupparis, Analyst. 1990, 115, 309.
11. I. C. Shukla, V. Shukla, Indian J. Chem. 1995, 34B, 461.
12. F. Belal, H. A. Al-Malaq, A. A. Al-Majed,J.Pharma.Biomed.Anal.2000, 23, 1005.
13. A. K. Bhattacharya, S. C. Dutta, S. C. Lahiri,Indian.J.Chem. 1990, 29A, 129.
14. N. A. A. Alar Faj, J. Pharm. Biomed. Anal. 2002, 28, 331.
15. M. Y. El-Maamli, Egyptian. J. Biomed. Sci. 2003, 11, 122.
16. S. M. Galal, S. M. Blain, Alexandria. J. Pharm. Sci. 1993, 7, 167.
17. M. N. Reddy, D. G. Sankar, K. Sreedharr, et al. Indian Drugs 1994, 31, 109.
18. R. S. Bakry, A. F. Elwalily, S. F. Belal, Anal. Lett. 1995, 28, 2503.
19. M. N. Reddy, D. G. Sankar, K. Sreedhar, et al. Indian Drugs 1996, 33, 420.
20. H. D. Revanasiddapa, B. G. Manju, J. AOAC Int. 2000, 83, 1440.
21. H. G. Daabees, Alexandria. J. Pharm. Sci. 2001, 15, 25.
22. M. S. Elazazy, A. Shalaby, M. N. Elbolkiny, et al. J. Chin. Pharm. 2003, 55, 481.
23. D. G. Sankar, C. S. P. Sastry, M. N. Reddy, et al. Indian Drugs 1989, 26, 348.
24. N. El-Enany, F. Belal, M. Rizk, Farmaco. 2002, 57, 641.
25. N. El-Enany, F. Belal, M. Rizk, Sci. Pharm. 2006, 74, 99.
26. C. Hartmann, J. Smeyers-Verbeke, W. Pinninckx, et al. Anal. Chem. 1995, 67, 4491.
27. J. Chrastil, J. Anal. Chem. 1975, 47, 2293.
28. D. G. Sankar, C. S. P. Sastry, M. N. Reddy, et al. Indian Drugs 1987, 24, 410.
29. Canadian Health Protection Branch, Drugs Directorate Guidelines, Acceptable methods, Ministry of National Health and Welfare: Draft, Ottawa, Canada, 1992.
30. D.M. Shingbal, H. S. Kudchadkar, Indian Drugs 1987, 24, 535.